Close
The page header's logo
Help
Login
Staff Login
Register
FR
0
Selected 
Invert selection
Deselect all
Deselect all
 Add to Cart
 Click here to refresh results
 Click here to refresh results
Go to Login page
 Hide details
doctype icon
Conceptually similar
Health Canada approves Pfizer COVID-19 treatment
play button
CP148756971 | Health Canada approves Pfizer COVID-19 treatment 
Pfizer COVID-19 antiviral pills arrive in SKorea
play button
CP148225771 | Pfizer COVID-19 antiviral pills arrive in SKorea 
COVID treatment improved but more are needed
play button
CP122266321 | COVID treatment improved but more are needed 
FDA gives full approval to Pfizer COVID-19 vaccine
play button
CP130270171 | FDA gives full approval to Pfizer COVID-19 vaccine 
FDA panel backs Pfizer's COVID-19 vaccine for kids
play button
CP138908121 | FDA panel backs Pfizer's COVID-19 vaccine for kids 
UK to begin Pfizer COVID-19 vaccine emergency use
play button
CP112461971 | UK to begin Pfizer COVID-19 vaccine emergency use 
Gov. promotes COVID treatment tied to donor
play button
CP129811110 | Gov. promotes COVID treatment tied to donor 
Saskatchewan to make federal COVID-19 app available
play button
CP19012721 | Saskatchewan to make federal COVID-19 app available 
Paxlovid is effective for treating COVID-19. Why is it underused?
play button
CP170009034 | Paxlovid is effective for treating COVID-19. Why is it underused? 
'Thank you:' Trudeau says to Pfizer works in Belgium
play button
CP125172021 | 'Thank you:' Trudeau says to Pfizer works in Belgium 
Action button

Why Pfizer needs time to make COVID-19 treatment

Pfizer’s new COVID-19 treatment came with a catch when it debuted late last year: Supplies were limited and it can take the company months to make the treatment. (Mar. 2) 
Actions
 Add to collection
 Add to cart
Information
Source name: 
The Associated Press
Unique identifier: CP151892840 
Legacy Identifier: 7c94cf7ddd66438b9cd54a7ae04eb84a 
Type: Video 
Duration: 1m46s 
Dimensions: 1920px × 1080px     125.31 MB 
Usage rights: Digital platform use only. Broadcast rights and editing of content prohibited. 
Create Date: 3/2/2022 10:19:28 AM 
Display aspect ratio: 16:9